2023 European Liver Annual Conference: Scientific Researchers Commenting on the Prospects of Cisplatin Targeted Immunotherapy AB359

At the first meeting of the European Liver Conference in 2023, Professor Matteo Iannacone from the Scientific Research Institute in Santa Fe, Italy, described AB359, a new preclinical in vivo trial data that further supports AB359 as a promising innovative immunotherapy for treating chronic HBV. The core content of this data is as follows:This study refers to selectively activating the IL-2 pathway in CD8+T cells to drive antiviral activity against hepatitis B virus (HBV)...

Tech >>